Rigosertib

small molecule

Identifier: CI-DRUG-00000520
Entity page: /drug/rigosertib ↗
Edges: 46

Neighbours: 19 cancers10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Rigosertib investigated for …INVESTIGATED_FOR10 of 10
→ investigated for	Chronic Myelomonocytic Leukemiahematologic_malignancy	unknown	3	Chronic Myelomonocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Myelodysplastic Syndromehematologic_malignancy	unknown	3

Rigosertib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 24show all (up to 200)
→ investigated in trials for	Solid Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myelomonocytic Leukemiahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myelomonocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Myelodysplastic Syndromehematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic Syndrome	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Anal Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cervical Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemia 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	1	Observed	clinicaltrials	graph →

Rigosertib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 24show all (up to 200)

→ investigated in trials for

Solid Neoplasm

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

Rigosertib studied in …STUDIED_INderived10 of 12show all (up to 200)
→ studied in	NCT05764395Phase 2 · terminated Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors · 12 trials list this drug (0 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04177498early Phase 1 · completed Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC · 12 trials list this drug (0 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04263090Phase 1/Phase 2 · completed Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment · 12 trials list this drug (0 active)	—	—	Adenocarcinoma,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01926587Phase 1/Phase 2 · completed Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine · 12 trials list this drug (0 active)	—	—	Myelodysplastic Syndrome,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02730884Phase 2 · terminated Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia · 12 trials list this drug (0 active)	—	—	Leukemia,Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT01928537Phase 3 · completed Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine · 12 trials list this drug (0 active)	—	—	Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia,Myelodysplastic Syndrome with Excess Blasts	1	Observed	clinicaltrials	graph →
→ studied in	NCT01167166Phase 1/Phase 2 · completed Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) · 12 trials list this drug (0 active)	—	—	Acute Lymphoblastic Leukemia,Myeloproliferative Neoplasm,Acute Myeloid Leukemia+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT01807546Phase 2 · completed Oral Rigosertib for Squamous Cell Carcinoma · 12 trials list this drug (0 active)	—	—	Anal Squamous Cell Carcinoma,Cervical Squamous Cell Carcinoma,Esophageal Squamous Cell Carcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT01168011Phase 1 · completed Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors · 12 trials list this drug (0 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01538537Phase 1 · completed Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer · 12 trials list this drug (0 active)	—	—	Neoplasm,Malignant Neoplasm,Solid Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths